Cardiovascular risk factors in chronic obstructive pulmonary disease: Results of the ARCE study;Asociación de factores de riesgo cardiovascular y EPOC. Resultados de un estudio epidemiológico (estudio ARCE)

Archivos de Bronconeumologia

Volumn 44, Issue 5, 2008, Pages 233-238

  De Lucas Ramos, Pilar ^a   Izquierdo Alonso, José Luis ^b   Moro, José Miguel Rodríguez González ^a   Bellón Cano, José María ^a   Ancochea Bermúdez, Julio ^c   Calle Rubio, Myrian ^d   Calvo Corbella, Eduardo ^e   Molina París, Jesús ^f   Pérez Rodríguez, Esteban ^g   Pons, Sonia ^h  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Centro de Salud Univ Pozuelo I   (Spain)

^f Centro de Salud Francia   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h Laboratorios Esteve   (Spain)

Author keywords

Cardiovascular risk; COPD; Prevalence

Indexed keywords

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FORCED EXPIRATION; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; PERIPHERAL VASCULAR DISEASE; POPULATION RESEARCH; PREDICTION; PREVALENCE;

EID: 45749121131     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13119937     Document Type: Article

References (29)

1. Instituto Nacional de Estadística. Tasas de mortalidad según causa, año 2002. Disponible en: http://www.inebase.es
2. Sobradillo V, Miravitlles M, Gabriel R, Masa JF, Viejo JL, Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study. Chest. 2000;118:981-9.
3. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003;22:809-14.
4. Huiart L, Erns P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128:2640-6.
5. Hole J, Watt GC, Davey-Smith, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-5.
6. Curkendall S, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
7. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome. Lancet. 2007;370:797-9.
8. Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis. 1997;52:43-7.
9. Mannino DM, Doherty DE, Buist S. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the atherosclerosis risk in communities (ARIC) study. Respir Med. 2006;100:115-22.
10. Nicholas R, Anthonisen MD, Melissa A, Skeans MS, Wise MD, Manfreda J, et al. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med. 2005;142:233-9.
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al; TORCH. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-89.
12. Izquierdo JL, Arroyo R. Enfermedad pulmonar obstructiva crónica y riesgo cardiovascular. Arch Bronconeumol. 2005;41:410-2.
13. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61:23-8.
14. De Torres JP, Córdoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902-7.
15. Izquierdo JL, Almonacid C, Parra T, Pérez J. Inflamación y estrés oxidativo en dos fenotipos de EPOC. Arch Bronconeumol. 2006;42:332-7.
16. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348:567-72.
17. Schünemann HJ, Dorn J, Grant BJB, Winkelstein W, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656-64.
18. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388-93.
19. García-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772-8.
20. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in the primary care. Chest. 2005;128:2099-107.
21. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 2000;160:2653-8.
22. Antonelli-Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
23. Curkendall SM, Lanes S, De Luise C, Stang MR, Jones JK, She D, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol. 2006;21:803-13.
24. Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosúa R, et al, for the VERIFICA investigators. Validity of an adaptation of the Framingham cardiovascular risk: the VERIFICA study. J Epidemiol Community Health. 2007;61:40-7.
25. Castell C, Tresserras R, Serra J, Godoy A, Lloveras G, Sallers L. Prevalence of diabetes in Catalonia (Spain): an oral glucosa tolerance test-based population study. Diabetes Res Clin Prac. 1999;43:33-40.
26. Aranceta J, Pérez Rodríguez C, Serra LL, Ribas Barba L, Quiles Izquierdo J, Vioque J, et al y el grupo colaborador para el estudio de la Obesidad en España. Prevalencia de la obesidad en España: resultados del estudio SEEDO 2000. Med Clin (Barc). 2003;120:608-12.
27. Villar Álvarez F, Benegas Benegas JR, Donado Campos J, Rodríguez Artalejo J. La enfermedad cardiovascular y sus factores de riesgo en España. Hechos y cifras. Informe de la Sociedad Española de Arteriosclerosis (SEA). Madrid: ERGON; 2005.
28. Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimaciones del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol. 2002;55:337-46.
29. Medrano-Alfaro MJ, Boix-Martínez R, Cerrato Crespan E, Ramres Santa-Pau M. Incidencia y prevalencia de cardiopatía isquémica y enfermedad cerebrovascular en España: revisión sistemática de la literatura. Rev Esp Salud Pública. 2006;80:5-15.